Production of plasminogen activator activity in factor XII deficient plasma
article
The authors studied the production of fibrinolytic activity in Hageman trait plasma, and conclude that the development of activator activity in euglobulin fractions is delayed, particularly in the Hageman trait plasma, by the presence of C1 inactivator, an inhibitor whose effect can be abolished by the synthetic compound flufenamic acid. Using flufenamic acid to decrease the inhibitory effects, the activator activity produced in Hageman trait plasma is high, but consistently lower than in normal plasma. © 1977 Published by Elsevier Inc. Chemicals/CAS: flufenamic acid, 1977-00-0, 530-78-9; plasminogen activator, 9039-53-6; blood clotting factor 12, 9001-30-3; complement component C1s inhibitor, 80295-37-0, 80295-38-1; Complement 1 Inactivators; Factor XII, 9001-30-3; Flufenamic Acid, 530-78-9; Plasminogen Activators, EC 3.4.21.-
Topics
flufenamic acidplasminogen activatorblood clotting factor 12complement component C1s inhibitorblood clotting factor 12 deficiencyin vitro studytheoretical studyblooddrug effectpHBlood Coagulation DisordersComplement 1 InactivatorsFactor XIIFibrinolysisFlufenamic AcidHumanHydrogen-Ion ConcentrationIn VitroPlasminogen Activators
TNO Identifier
228175
ISSN
00493848
Source
Thrombosis Research, 10(5), pp. 759-764.
Pages
759-764
Files
To receive the publication files, please send an e-mail request to TNO Repository.